Interim report
Page 1
Q3 2026 Interim report January - September
Page 2
Vimian Group Interim report January - September 2026 2 Interim report January - September 2026 Continued strong performance Third quarter ▪ Revenue increased by 15 per cent to EUR 120.3m (104.3) with organic growth of 11 per cent. Acquisitions contributed with 3 per cent and positive impact from currency movements of 1 per cent ▪ Operating profit (EBIT) of EUR 20.5m (17.5) ▪ EBITA of EUR 27.1m (23.9), including items affecting comparability of EUR -2.1m (-1.7). Adjusted EBITA increased 14 per cent to EUR 29.2m (25.5) corresponding to a margin of 24.3 per cent (24.5) ▪ Profit for the period of EUR 9.3m (6.8) and earnings per share before and after dilution EUR 0.02 (0.01) ▪ Cash flow from operating activities of EUR 22.6m (10.8) First nine months ▪ Revenue increased by 13 per cent to EUR 357.9m (316.1) with organic growth of 10 per cent. Acquisitions contributed with 4 per cent and negative impact from currency movements of -2 per cent. ▪ Operating profit (EBIT) of EUR 64.0m (47.6) ▪ EBITA of EUR 83.3m (65.2), including items affecting comparability of EUR -4.8m (-14.0). Adjusted EBITA increased 11 per cent to EUR 88.1m (79.2) corresponding to a margin of 24.6 per cent (25.1) ▪ Profit for the period of EUR 28.1m (20.1) and earnings per share before and after dilution EUR 0.05 (0.04) ▪ Cash flow from operating activities of EUR 49.4m (50.1) Significant events during the third quarter ▪ On 17 July, the Board resolved to carry out a new issue and subsequently repurchase a total of 2,673,064 shares, of which 1,721,174 class D shares, 475,945 class E1 2026 shares and 475,945 class E2 2026 shares as part of the implementation of LTI2026. ▪ On 27 August, Vimian appointed Hans Lord Skarplöth as Head of Specialty Pharma and member of the Vimian Group Management Team, effective 1 October. ▪ The number of votes in Vimian changed during August as a result of the conversion of a total of 166,405 C shares into an equal number of ordinary shares and the number of votes has increased by 149,764.5. ▪ On 14 September, Martin Bengtson, Head of M&A and member of the Vimian Group management team, decided to step down and Andrea Tidholm was appointed new Head of M&A reporting into CFO Carl-Johan Zetterberg Boudrie, effective 5 October. Significant events after the third quarter ▪ No significant events occurred after the end of the third quarter.
Page 3
Vimian Group Interim report January - September 2026 3 Financial key ratios 1 Refer to the section on Alternative performance measures for more information. 2 Refer to Note 3 and the section on Items affecting comparability for more information. EURm,Jul-SepJul-SepJan-SepJan-SepOct-SepFull-yearunless otherwise stated 2026 2025 Δ% 2026 2025 Δ% 25/26 2025Revenue 120.3 104.315%357.9 316.113%466.9 425.0Organic revenue growth (%)¹ 11% 9% 10% 6% 6%EBITA 27.1 23.914%83.3 65.228%108.8 90.7EBITA margin (%) 22.5% 22.9%-0.4 pp23.3% 20.6%2.7 pp23.3% 21.3%Adjusted EBITA¹ 29.2 25.514%88.1 79.211%114.3 105.3Adjusted EBITA margin (%)¹ 24.3% 24.5%-0.2 pp24.6% 25.1%-0.4 pp24.5% 24.8%Operating profit (EBIT) 20.5 17.517%64.0 47.634%83.3 66.8Profit for the period 9.3 6.836%28.1 20.140%40.3 32.3Items affecting comparability² -2.1 -1.7 -4.8 -14.0 -5.5 -14.7Earnings per share before dilution (EUR) 0.02 0.01 0.05 0.04 0.07 0.06Earnings per share after dilution (EUR) 0.02 0.01 0.05 0.04 0.07 0.06Cash flow from operating activities 22.6 10.8110%49.4 50.1-1%105.1 105.7
Page 4
Vimian Group Interim report January - September 2026 4 Message from our CEO Continued strong performance Vimian delivered another quarter with double-digit organic revenue growth and strong earnings growth. Total revenues grew 15 per cent to EUR 120.3 million with organic growth of 11 per cent. Our business continues to outperform the overall animal health market, reflecting the strength of our strategy with focus on attractive market niches, a strong brand portfolio and disciplined execution of our teams in an entrepreneurial organisation. Adjusted EBITA grew 14 per cent to EUR 29.2 million with strong growth across all four segments. The adjusted EBITA margin reached 24.3 per cent (24.5). Cash flow from operating activities improved compared to the second quarter and reached EUR 22.6 million. After the end of the quarter, we signed the acquisition of Norfolk Medical Products to our MedTech segment, adding USD 6.9 million in annual revenues. The acquisition expands our offering into specialised soft tissue surgery, a high growth niche within veterinary surgery. Specialty Pharma – underlying momentum remains strong Specialty Pharma delivered 7 per cent organic growth driven by the therapeutic areas Allergy, Dermatology and Specialty Pharmaceuticals. As previously communicated, Specialised Nutrition was negatively impacted by a strong prior year comparison which included a national sales campaign in US that we completed in the second quarter of this year. During the quarter we launched an updated version of our allergy test platform Pet Allergy Explorer (PAX), that covers an additional 25 allergens. PAX is the world’s most advanced veterinary allergy test, and several scientific studies reaffirm the test platform’s ability to outperform other blood-based allergy tests on the market. The adjusted EBITA margin improved to 30.3 per cent (29.5). MedTech – continued double-digit growth MedTech achieved 15 per cent organic growth, with the dental business continuing to deliver strong growth, driven by disciplined commercial execution and deepened penetration of key customer accounts in the US in a market niche with unmet medical needs. We also see continued positive momentum in our orthopedics business, including the previously underperforming North American market, where we delivered another quarter of growth. We educated 1,300 veterinarians in the quarter to unlock long-term market growth in both orthopedics and dentistry. The adjusted EBITA margin improved to 24.4 per cent (23.7), driven by the dental business. Veterinary Services – momentum remains Veterinary Services delivered 10 per cent organic growth in the quarter, and we entered the new markets Portugal and Japan, with positive feedback on our service offering from the veterinary community. The adjusted EBITA margin improved to 30.5 per cent (29.1), including positive effects in the quarter from mix and our strategic partner agreements. Diagnostics – focus on companion animal Diagnostics delivered 13 per cent organic growth in the quarter driven by extraction and PCR test sales in the livestock business. The adjusted EBITA margin was 7.2 per cent (4.9), including our investments to diversify into companion animal diagnostics. Clear progress across strategic initiatives Our business is performing well, and we are making clear progress across our strategic initiatives. The M&A pipeline remains active, including both possible platform as well as bolt-on acquisitions. During the quarter, we announced the recruitment of Hans Lord Skarplöth as Head of Specialty Pharma, and the promotion of Andrea Tidholm as Head of M&A. Our bi-annual employee survey, conducted in September, showed continued high employee engagement scores. In September, we also held our global Vimian leadership conference, further strengthening our cross-company culture and collaboration across the Group. Looking ahead, we are well positioned to continue delivering sustainable, volume-led growth, supported by our diversified portfolio and multiple revenue streams. Our strong reputation as a preferred home for successful animal health entrepreneurs further strengthens our ability to build a global leader in attractive animal health niches through a combination of organic growth and disciplined acquisitions. On 24 November, we will host a Capital Markets Day in Stockholm to provide further insights into our strategy and the roadmap towards the 2030 financial target. Alireza Tajbakhsh CEO of Vimian Group AB (publ)
Page 5
Vimian Group Interim report January - September 2026 5 Group performance Third quarter 2026 Revenue Revenue increased by 15 per cent to EUR 120.3m (104.3). Organic revenue growth was 11 per cent driven by Specialty Pharma and MedTech with 7 per cent and 15 per cent organic growth respectively. Veterinary Services organic growth was 10 per cent. Diagnostics delivered organic growth of 13 per cent. Acquisitions contributed with 3 per cent and positive impact of 1 per cent from currency movements. Operating profit Operating profit (EBIT) amounted to EUR 20.5m (17.5) at a margin of 17.0 per cent (16.8). This includes items affecting comparability of EUR -2.1m (-1.7). Main items affecting comparability relates to acquisition costs in MedTech and Veterinary Services of EUR 1.4m and reorganisation cost in Specialty Pharma EUR 0.3m. For further information on items affecting comparability, refer to Note 3. EBITA EBITA increased by 14 per cent to EUR 27.1m (23.9) at a margin of 22.5 per cent (22.9). Adjusted EBITA Adjusted EBITA increased by 14 per cent to EUR 29.2m (25.5) at a margin of 24.3 per cent (24.5). Financial items Net financial items amounted to EUR -6.9m (-4.1). This consists of three main parts: (1) financing expenses of EUR -4.2m with an average interest rate of 4.0 per cent during the quarter, partly offset by interest income of EUR 0.8m; (2) a quarterly discounting impact of EUR -0.9m and negative impact of EUR -2.2m from probability adjustments related to contingent considerations; (3) a negative impact of EUR -0.5m from exchange rate effects on the revaluation of debt. Tax Income tax expense for the quarter was EUR -4.3m (-6.6) at an effective tax rate of 31 per cent. In the quarter the tax expense as percentage of pre-tax profit was negatively affected by probability adjustments related to contingent considerations and other non-deductible expenses. Profit for the period Profit for the period amounted to EUR 9.3m (6.8), negatively impacted by EUR -0.5m from exchange rates included in financial items and by EUR -2.2m from probability adjustment on contingent liabilities. Earnings per share before and after dilution amounted to EUR 0.02 (0.01). Cash flow Cash flow from operating activities amounted to EUR 22.6m (10.8). Cash flow from investing activities of EUR -21.0m (-5.1) primarily consisting of acquisitions and earn-out payments. Cash flow from financing activities amounts to EUR 2.4m (-22.0). Net working capital Net working capital amounted to EUR 116.4m (102.2) per the end of September at 25 (25) per cent of revenue, an increase from EUR 114.1m at the end of June 2026 (26 per cent of revenue). The increase in net working capital compared to last year is mainly driven by higher inventories in MedTech to manage strong demand in the dental business. Compared to end of June 2026, net working capital increased by EUR 2.3m. Quarterly revenue Quarterly adjusted EBITA -20406080100120140Q32024Q42024Q12025Q22025Q32025Q42025Q12026Q22026Q32026EURm 0%5%10%15%20%25%30%-5101520253035Q32024Q42024Q12025Q22025Q32025Q42025Q12026Q22026Q32026EURmAdj EBITAAdj EBITA-margin (%)
Page 6
Vimian Group Interim report January - September 2026 6 Capital expenditure Capital expenditure amounted to EUR -4.1m (-3.1). This is split between EUR -2.9m investments in intangible assets (internal R&D, software development and R&D partnerships) and EUR - 1.2m investments in property, plant and equipment. The capex of EUR -4.1m accounts for 3.4 per cent of sales, compared to 2.9 per cent for the same period in the previous year. The higher capex as a percentage of sales is due to higher investments in capitalized R&D as well as investments in premises. Net debt and cash and cash equivalents At the end of the period, net debt amounted to EUR 262.4m (253.5), a decrease from EUR 273.7m per 30 June 2026. Cash and cash equivalents amounted to EUR 55.6m (51.3) an increase compared to EUR 51.6m at the end of June. External lending amounted to EUR 263.1m (254.0). Per 30 September, net debt in relation to pro-forma adjusted EBITDA over the past 12-month period was 2.0x, a decrease from 2.1x per 30 June 2026. Central Costs Central costs amounted to EUR -3.0m (-1.8). Central costs include EUR -0.6m expenses related to the 2024, 2025 and 2026 long term incentive programmes (employee stock options and investment shares). These are non-cash IFRS expenses that will recur for the duration of the three-year programs.
Page 7
Vimian Group Interim report January - September 2026 7 January to September 2026 Revenue Revenue increased by 13 per cent to EUR 357.9m (316.1). Organic revenue growth was 10 per cent driven by Specialty Pharma and MedTech with 11 per cent organic growth respectively. Veterinary Services organic growth was 10 per cent. Diagnostics delivered organic growth of 11 per cent. Acquisitions contributed with 4 per cent and negative impact of -2 per cent from currency movements. Operating profit Operating profit (EBIT) amounted to EUR 64.0m (47.6) at a margin of 17.9 per cent (15.1). This includes items affecting comparability of EUR -4.8m (-14.0). Most items affecting comparability relates to acquisition costs in MedTech, Veterinary Services and Diagnostics of EUR -3.2m. In MedTech, the litigation costs in the US indemnification dispute amounted to EUR -1.1m. For further information on items affecting comparability, refer to Note 3. EBITA EBITA increased by 28 per cent to EUR 83.3m (65.2) at a margin of 23.3 per cent (20.6). Adjusted EBITA Adjusted EBITA increased by 11 per cent to EUR 88.1m (79.2) at a margin of 24.6 per cent (25.1). Financial items Net financial items amounted to EUR -18.2m (-13.1). This consists of three main parts: (1) financing expenses of EUR -10.5m, with an average interest rate of 4.0 per cent during the period, partly offset by interest income of EUR 1.2m; (2) a discounting impact of EUR - 3.2m and negative impact of EUR -4.5m from probability adjustments related to contingent considerations; (3) a negative impact of EUR - 1.2m from exchange rate effects on the revaluation of debt. Tax Income tax expense for the period was EUR -15.1m (-14.3) at an effective tax rate of 35 per cent. The tax expense as percentage of pre-tax profit was negatively affected by probability adjustments related to contingent considerations and other non-deductible expenses. Profit for the period Profit for the period amounted to EUR 28.1m (20.1), negatively impacted by EUR -1.2m from exchange rates included in financial items and by EUR -4.5m from probability adjustment on contingent liabilities. Earnings per share before and after dilution amounted to EUR 0.05 (0.04). Cash flow Cash flow from operating activities amounted to EUR 49.4m (50.1). Cash flow from investing activities of EUR -77.5m (-95.3) primarily consisting of acquisitions and earn-out payments. Cash flow from financing activities amounts to EUR 28.0m (34.2). Capital expenditure Capital expenditure amounted to EUR -15.6m (-9.3). This is split between EUR -7.7m investments in intangible assets (internal R&D, software development and R&D partnerships) and EUR -7.9m investments in property, plant and equipment (the larger investments include leasehold improvements and expansion of premises in MedTech and Specialty Pharma). Central Costs Central costs amounted to EUR -8.9m (-6.2). Central costs include EUR -1.8m expenses related to the 2024, 2025 and 2026 long term incentive programmes (employee stock options and investment shares). These are non-cash IFRS expenses that will recur for the duration of the three-year programs.
Page 8
Vimian Group Interim report January - September 2026 8 Segment performance Third quarter 2026 Vimian operates through four reporting segments: Specialty Pharma, MedTech, Veterinary Services and Diagnostics Revenue Adjusted EBITA Jul-SepJul-SepJan-SepJan-SepOct-Sep Full-yearEURm2026 2025 Δ 2026 2025Δ 25/26 2025Specialty Pharma 50.3 46.29%149.0 136.49%195.0 182.4MedTech 43.2 37.116%130.4 115.413%170.6 155.5Veterinary Services 19.3 15.822%56.2 47.518%73.0 64.3Diagnostics 7.4 5.244%22.2 16.832%28.3 22.9Group120.3 104.315%357.9 316.113%466.9 425.0Jul-SepJul-SepJan-SepJan-SepOct-Sep Full-yearEURm2026 2025 Δ 2026 2025Δ 25/26 2025Specialty Pharma 15.2 13.612%45.0 40.112%58.8 53.9MedTech 10.5 8.820%33.6 29.713%43.5 39.6Veterinary Services 5.9 4.628%16.2 13.916%20.7 18.4Diagnostics 0.5 0.3111%2.2 1.636%2.8 2.2Group Functions -3.0 -1.870%-8.9 -6.244%-11.5 -8.8Group29.2 25.514%88.1 79.211%114.3 105.3 Revenue per segment, Q3 2026 Adjusted EBITA per segment, Q3 20261 1 Adjusted EBITA before central costs. 42%36%16%6%Specialty PharmaMedTechVeterinary ServicesDiagnostics47%33%18%2%Specialty PharmaMedTechVeterinary ServicesDiagnostics
Page 9
Vimian Group Interim report January - September 2026 9 Segment – Specialty Pharma Revenue Revenue in the third quarter grew 9 per cent to EUR 50.3 million (46.2). Organic growth was 7 per cent, with no contribution from acquisitions and 2 per cent positive impact from currency movements. Growth was driven by double-digit organic growth in three out of four therapeutic areas. The therapeutic area Specialised Nutrition was negatively impacted by a strong prior year comparison which included a national sales campaign in US that was completed in the second quarter of this year. Adjusting for the impact from these campaigns, organic growth in Specialty Pharma was 11 per cent in the third quarter. 12 new products were launched during the third quarter. Net revenue during January to September grew 9 per cent to EUR 149.0 million (136.4). Organic growth of 11 per cent, with no contribution from acquisitions and -1 per cent negative impact from currency movements. Adjusted EBITA Adjusted EBITA in the third quarter increased by 12 per cent to EUR 15.2 million (13.6) at a margin of 30.3 per cent (29.5). The year-over- year margin improvement was driven by revenue growth and an improved gross margin. Adjusted EBITA for the period January to September increased by 12 per cent to EUR 45.0 million (40.1) at a margin of 30.2 per cent (29.4). Jul-SepJul-SepJan-SepJan-SepOct-SepFull-yearEURm2026 2025 Δ 2026 2025Δ25/26 2025Revenue 50.3 46.29%149.0 136.49%195.0 182.4Organic revenue growth (%) 7% 11%-4 pp 11% 9%2 pp 8%EBITA 14.8 13.69%44.3 39.612%58.0 53.3EBITA margin (%) 29.5% 29.5%-0.0 pp29.8% 29.1%0.7 pp29.8% 29.2%Adjusted EBITA 15.2 13.612%45.0 40.112%58.8 53.9Adjusted EBITA margin (%) 30.3% 29.5%0.8 pp30.2% 29.4%0.8 pp30.2% 29.6% Quarterly revenue Specialty Pharma Quarterly adjusted EBITA Specialty Pharma 30405060Q32024Q42024Q12025Q22025Q32025Q42025Q12026Q22026Q32026EURm 20%30%40%-48121620Q32024Q42024Q12025Q22025Q32025Q42025Q12026Q22026Q32026EURmAdj EBITAAdj EBITA-margin (%)
Page 10
Vimian Group Interim report January - September 2026 10 Segment – MedTech Revenue Revenue in the third quarter increased 16 per cent to EUR 43.2 million (37.1). Organic growth of 15 per cent, with no contribution from acquisitions and 2 per cent positive impact from currency movements. Organic growth was driven by continued double-digit growth in both the dental and the orthopedics business. In the dental business, North America and Asia-Pacific delivered strong growth, and in orthopedics growth was mainly driven by Europe and Asia-Pacific. The orthopedics business in North America delivered low single-digit organic growth in the quarter. Net revenue during January to September grew 13 per cent to EUR 130.4 million (115.4). Organic growth of 11 per cent, with 5 per cent contribution from acquisitions in veterinary dental and -2 per cent negative impact from currency movements. Adjusted EBITA Adjusted EBITA in the third quarter increased by 20 per cent to EUR 10.5 million (8.8) at a margin of 24.4 per cent (23.7). The margin improvement was driven by strong growth and improved gross margin in the dental business. Adjusted EBITA for the period January to September increased by 13 per cent to EUR 33.6 million (29.7) at a margin of 25.8 per cent (25.8). Jul-Sep Jul-Sep Jan-Sep Jan-Sep Oct-Sep Full-yearEURm2026 2025 Δ 2026 2025 Δ 25/26 2025Revenue 43.2 37.116%130.4 115.413%170.6 155.5Organic revenue growth (%) 15% 5%9 pp 11% - 3%13 pp- 1%EBITA 9.4 7.821%30.9 19.558%41.3 29.9EBITA margin (%) 21.7% 20.9%0.8 pp23.7% 16.9%6.8 pp24.2% 19.2%Adjusted EBITA 10.5 8.820%33.6 29.713%43.5 39.6Adjusted EBITA margin (%) 24.4% 23.7%0.6 pp25.8% 25.8%0.0 pp25.5% 25.5% Quarterly revenue MedTech Quarterly adjusted EBITA MedTech -1020304050Q32024Q42024Q12025Q22025Q32025Q42025Q12026Q22026Q32026EURm 0%10%20%30%40%-3691215Q32024Q42024Q12025Q22025Q32025Q42025Q12026Q22026Q32026EURmAdj EBITAAdj EBITA-margin (%)
Page 11
Vimian Group Interim report January - September 2026 11 Segment – Veterinary Services Revenue Revenue for the third quarter grew 22 per cent to EUR 19.3 million (15.8). Organic growth of 10 per cent, with 13 per cent contribution from acquisitions and no impact from currency movements. The member base continued to increase reaching 12,400 members by the end of the third quarter. The combination of continued growth in new members, an increased share of wallet and strategic partnerships supported the organic growth, with strong development in the US. Co-owned clinics accounted for approximately a third of segment revenue and delivered low single-digit growth in the quarter. Net revenue during January to September grew 18 per cent to EUR 56.2 million (47.5). Organic growth of 10 per cent, with 9 per cent contribution from acquisitions and -1 per cent negative impact from currency movements. Adjusted EBITA Adjusted EBITA for the third quarter increased 28 per cent to EUR 5.9 million (4.6) at a margin of 30.5 per cent (29.1). The year-over-year margin improvement was mainly driven by mix towards higher-margin services as well as positive effects in the quarter from our strategic partner agreements. Adjusted EBITA for the period January to September increased by 16 per cent to EUR 16.2 million (13.9) at a margin of 28.8 per cent (29.3) Jul-Sep Jul-Sep Jan-Sep Jan-Sep Oct-Sep Full-yearEURm2026 2025 Δ 2026 2025 Δ 25/26 2025Revenue 19.3 15.822%56.2 47.518%73.0 64.3Organic revenue growth (%) 10% 11%-2 pp 10% 12%-2 pp 11%EBITA 5.5 4.620%14.1 13.82%18.3 18.0EBITA margin (%) 28.5% 29.1%-0.7 pp25.1% 29.0%-4.0 pp25.1% 28.1%Adjusted EBITA 5.9 4.628%16.2 13.916%20.7 18.4Adjusted EBITA margin (%) 30.5% 29.1%1.4 pp28.8% 29.3%-0.6 pp28.3% 28.6% Quarterly revenue Veterinary Services Quarterly adjusted EBITA Veterinary Services -5101520Q32024Q42024Q12025Q22025Q32025Q42025Q12026Q22026Q32026EURm 0%10%20%30%40%-2468Q32024Q42024Q12025Q22025Q32025Q42025Q12026Q22026Q32026EURmAdj EBITAAdj EBITA-margin (%)
Page 12
Vimian Group Interim report January - September 2026 12 Segment – Diagnostics Revenue Revenue in the third quarter increased by 44 per cent to EUR 7.4 million (5.2). Organic growth of 13 per cent, with 30 per cent contribution from acquisitions and 1 per cent positive impact from currency movements. Organic growth was mainly driven by sales of extraction and PCR products in the livestock business. The companion animal diagnostics business, including I-Vet, continued to deliver strong growth. Net revenue during January to September grew 32 per cent to EUR 22.2 million (16.8). Organic growth of 11 per cent, with 22 per cent contribution from acquisitions and no impact from currency movements. Adjusted EBITA Adjusted EBITA for the third quarter amounted to EUR 0.5 million (0.3) at a margin of 7.2 per cent (4.9). The margin improvement was driven by revenue growth, partly offset by continued investments in the companion animal diagnostics business. Adjusted EBITA for the period January to September increased by 36 per cent to EUR 2.2 million (1.6) at a margin of 9.9 per cent (9.7). Jul-Sep Jul-Sep Jan-Sep Jan-Sep Oct-Sep Full-yearEURm2026 2025 Δ 2026 2025 Δ 25/26 2025Revenue 7.4 5.244%22.2 16.832%28.3 22.9Organic revenue growth (%) 13% 4%9 pp 11% 13%-2 pp 10%EBITA 0.4 0.2153%1.7 1.418%1.7 1.4EBITA margin (%) 5.3% 3.0%2.3 pp7.6% 8.5%-0.9 pp6.0% 6.3%Adjusted EBITA 0.5 0.3111%2.2 1.636%2.8 2.2Adjusted EBITA margin (%) 7.2% 4.9%2.3 pp9.9% 9.7%0.2 pp9.8% 9.5% Quarterly revenue Diagnostics Quarterly adjusted EBITA Diagnostics -2468Q32024Q42024Q12025Q22025Q32025Q42025Q12026Q22026Q32026EURm 0%10%20%- 0.5 1.0 1.5Q32024Q42024Q12025Q22025Q32025Q42025Q12026Q22026Q32026EURmAdj EBITAAdj EBITA-margin (%)
Page 13
Vimian Group Interim report January - September 2026 13 Declaration of the Board of Directors and Chief Executive Officer The Board of Directors and Chief Executive Officer declare that the interim report provides a true and fair view of the development of the Group’s and parent company’s business, its financial position and results, and describes significant risks and uncertainties faced by the parent company and the companies included in the Group. Stockholm, 22 October 2026 Magnus Welander Chairman Gabriel Fitzgerald Pia Marions Petra Rumpf Theodor Bonnier Alireza Tajbakhsh Group CEO This report has been reviewed by the company’s auditors. Prior to publication this information constituted inside information that Vimian Group AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the above contact persons, at 07:45 am CEST on 22 October 2026. Webcast conference call on 22 October 2026: In connection with the interim report, Vimian will hold a webcast conference call in English at 09:00 am CEST. Vimian will be represented by CEO Alireza Tajbakhsh and CFO Carl-Johan Zetterberg Boudrie, who will present the interim report and answer questions. Information regarding telephone numbers is available at www.vimian.com/investors. The presentation will be available at www.vimian.com/investors after publication of the interim report. The webcast will be available at the same address after the live broadcast.
Page 14
Vimian Group Interim report January - September 2026 14 Report on Review of Interim Financial Information Introduction We have reviewed the interim financial information (interim report) for Vimian Group AB per 30 September 2026 and for the nine-month period then ended. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim financial information based on our review. Scope of Review We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity.” A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Conclusion Based on our review, nothing has come to our attention that causes us to believe that the interim report is not, in all material respects, prepared for the Group in accordance with IAS 34 and the Annual Accounts Act, and for the Parent Company in accordance with the Annual Accounts Act. Stockholm 22 October 2026 Grant Thornton Sweden AB Camilla Nilsson Authorized Public Accountant
Page 15
Vimian Group Interim report January - September 2026 15 INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Jul-SepJul-SepJan-SepJan-SepFull-yearEURm unless otherwise statedNote2026 2025 2026 2025 2025Revenue from contracts with customers3, 4 120.3 104.3 357.9 316.1 425.0Revenue120.3 104.3 357.9 316.1 425.0Other operating income10 1.1 0.6 3.6 2.3 3.3Raw material and merchandise-36.8 -32.0 -110.1 -96.9 -132.2Other external expenses10 -20.3 -18.7 -61.5 -64.4 -81.4Personnel expenses-32.1 -26.5 -91.7 -80.5 -108.2Depreciation and amortisation-11.3 -9.9 -32.0 -27.8 -37.9Other operating expenses-0.4 -0.3 -2.2 -1.2 -1.8Operating profit20.5 17.5 64.0 47.6 66.8Net financial items-6.9 -4.1 -18.1 -13.1 -20.6Share of profit of an associate-0.0 - -2.5 - -0.3Profit before tax13.6 13.4 43.3 34.4 45.9Income tax expense-4.3 -6.6 -15.1 -14.3 -13.5Profit for the period9.3 6.8 28.1 20.1 32.3Profit for the period attributable to:Equity holders of the parent8.9 6.5 27.1 19.2 31.3Non-controlling interests0.4 0.3 1.1 1.0 1.1Earnings per share, before dilution (EUR)0.02 0.01 0.05 0.04 0.06Earnings per share, after dilution (EUR)0.02 0.01 0.05 0.04 0.06Average number of shares, before dilution (Thousands) 532,438 526,707 530,357 524,960 525,701Average number of shares, after dilution (Thousands) 535,146 526,820 533,066 525,072 525,701Number of shares at the end of the period (Thousands) 533,319 526,903 533,319 526,903 529,263Jul-Sep Jul-Sep Jan-Sep Jan-Sep Full-yearEURmNote2026 2025 2026 2025 2025Profit for the period9.3 6.8 28.1 20.1 32.3Other comprehensive income Items that may be reclassified to profit or loss:Exchange differences on translation of foreign operations9.2 -3.5 17.8 -41.5 -41.5Remeasurement of interest derivatives to fair value-3.9 - 1.3 - -Items that will not be reclassified to profit or loss:Remeasurement of defined benefit plans-0.0 0.0 0.1 0.1 -0.0Other comprehensive income for the period, net of tax5.3 -3.5 19.2 -41.4 -41.5Total comprehensive income for the period, net of tax14.6 3.3 47.3 -21.3 -9.2Total comprehensive income attributable to:Equity holders of the parent13.5 3.0 45.6 -20.5 -8.7Non-controlling interests1.0 0.3 1.7 -0.8 -0.4
Page 16
Vimian Group Interim report January - September 2026 16 INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION EURm Note30 Sep 2026 30 Sep 2025 31 Dec 2025Non-current assetsGoodwill 626.5 589.0 590.1Intangible assets 239.0 240.4 238.9Property, plant and equipment 37.8 29.7 31.6Right-of-use assets 16.4 15.4 14.8Investment in associates 13.0 9.3 14.1Non-current financial assets 2.1 24.6 1.5Deferred tax assets 6.8 1.5 5.2Total non-current assets 941.6 909.9 896.3Current assetsInventories 98.3 80.9 80.1Trade receivables 67.5 57.6 57.3Current tax receivables 4.5 2.2 1.2Other receivables 6.9 8.5 6.7Prepaid expenses and accrued income 14.6 12.2 13.2Cash and cash equivalents 55.6 51.3 55.0Total current assets 247.4 212.6 213.5TOTAL ASSETS 1,189.0 1,122.5 1,109.8 EURm Note30 Sep 2026 30 Sep 2025 31 Dec 2025EquityShare capital 0.1 0.1 0.1Other contributed capital 629.7 625.1 626.4Reserves -19.4 -36.2 -36.5Retained earnings including this period’s profit 137.5 97.0 109.0Total equity attributable to equity holders of the parent 747.9 686.1 699.0Non-controlling interests 11.0 9.6 9.9Total equity 758.9 695.7 708.9Non-current liabilitiesBonds 150.0 150.0 150.0Liabilities to credit institutions 113.1 104.0 73.3Lease liabilities 12.1 11.0 10.3Deferred tax liabilities 34.7 36.9 35.5Other non-current liabilities 28.2 28.8 20.9Non-current provisions 1.3 1.5 1.6Total non-current liabilities339.5332.2291.6Current liabilitiesLease liabilities 5.0 5.0 5.1Trade payables 28.1 18.5 20.1Current tax liabilities 10.3 10.6 10.3Other current liabilities 21.4 38.8 53.9Accrued expenses and prepaid income 24.1 21.4 19.2Provisions1.60.30.8Total current liabilities 90.6 94.6 109.4TOTAL EQUITY AND LIABILITIES 1,189.0 1,122.5 1,109.8
Page 17
Vimian Group Interim report January - September 2026 17 IN TERIM CONDENSED CONSOLIDATED STATEMENT OF CH ANGES IN EQUITY EURmShare capital Other contributed capital Translation reserve Retained earnings including this period’s profit Total equity attributable to equity holders of the parent Non-controlling interests Total equity Opening balance 1 January 2025 0.1 614.9 3.5 81.5 699.9 6.6 706.5 Profit for the period 19.2 19.2 1.0 20.1Other comprehensive income -39.6 -39.6 -1.7 -41.4Total comprehensive income - - -39.6 19.2 -20.4 -0.8 -21.2 Transactions with owners Share issue 10.1 10.1 10.1Transaction costs -0.1 -0.1 -0.1Warrant programme 0.4 0.4 0.4Transactions with non-controlling interests -3.7 -3.7 3.7 -Total - 10.3 - -3.7 6.6 3.7 10.3 Closing balance 30 September 2025 0.1 625.1 -36.2 97.0 686.1 9.6 695.7Opening balance 1 January 2026 0.1 626.4 -36.5 109.0 699.0 9.9 708.9 Profit for the period 27.1 27.1 1.1 28.1Other comprehensive income 17.1 1.4 18.6 0.6 19.2Total comprehensive income - - 17.1 28.5 45.6 1.7 47.3 Transactions with owners Share issue 0.0 3.5 3.5 3.5Transaction costs -0.1 -0.1 -0.1Warrant program -0.0 -0.0 -0.0Transactions with non-controlling interests -0.1 -0.1 -0.6 -0.6Total 0.0 3.4 - -0.1 3.3 -0.6 2.8 Closing balance 30 September 2026 0.1 629.7 -19.4 137.5 747.9 11.0 758.9 Equity attributable to equity holders of the parent
Page 18
Vimian Group Interim report January - September 2026 18 INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Jul-SepJul-SepJan-SepJan-SepFull-yearEURm2026 2025 2026 2025 2025Operating activitiesOperating profit20.5 17.5 64.0 47.6 66.8Adjustments for non-cash items10.9 8.8 33.0 40.4 54.4Interest received0.5 0.4 1.2 1.4 1.2Interest paid-3.3 -4.0 -9.8 -10.0 -15.7Paid income tax-6.3 -9.0 -23.7 -13.3 -17.4Cash flow from operating activities before change in working capital 22.2 13.7 64.7 66.1 89.3Change in inventories -4.7 -1.1 -16.5 -7.6 -6.7Change in operating receivables4.4 3.3 -11.3 -6.1 20.9Change in operating liabilities0.6 -5.1 12.4 -2.3 2.3Cash flow from operating activities22.6 10.8 49.4 50.1 105.7Investing activitiesAcquisition of a subsidiary, net of cash acquired, Note 5 and 6-16.3 -1.3 -62.6 -87.2 -92.2Investments in associates-0.4 -0.0 -0.4 -0.0 -5.1Proceeds from sale of associates- - - - 0.1Investments in intangible assets-2.9 -1.2 -7.7 -3.6 -6.0Proceeds from sale of intangible assets0.3 - 1.4 -Investments in property, plant and equipment-1.2 -1.9 -7.9 -5.7 -9.1Proceeds from sale of property, plant and equipment-0.0 0.0 -0.0 0.0 0.1Investments in financial assets-0.4 -0.7 -0.3 1.3 -0.5Cash flow from investing activities-21.0 -5.1 -77.5 -95.3 -112.8Financing activitiesNew share issue-0.0 - 3.4 10.1 10.5Warrant program0.0 0.2 - 0.4 -0.0Share issue - Transaction costs- -0.1 - -0.1 -0.1Proceeds from borrowings17.9 -0.4 60.3 272.4 277.8Repayment of borrowings -13.6 -20.5 -31.0 -245.0 -284.1Payment of lease liabilities-1.5 -1.2 -4.3 -3.6 -4.9Transactions with non-controlling interests-0.4 - -0.4 - -0.4Cash flow from financing activities2.4 -22.0 28.0 34.2 -1.2Cash flow for the period4.0 -16.3 -0.1 -11.0 -8.3Cash and cash equivalents at beginning of the period51.6 67.5 55.0 64.8 64.8Exchange-rate difference in cash and cash equivalents0.0 - 0.6 -2.6 -1.5Cash and cash equivalents at end of the period55.651.355.651.355.0
Page 19
Vimian Group Interim report January - September 2026 19 CONDENSED PARENT COMPANY INCOME STATEMENT AND BALANCE SHEET 1 Net Financial items for the year includes interest income of SEK 239.0m (255.6), dividend from subsidiary 0.0 (95.0), interest expenses (including bank fees) of SEK -116.5 (-127.9) and exchange rate differences of SEK 247.5 (-400.1). Jul-Sep Jul-Sep Jan-Sep Jan-Sep Full-yearSEKm2026 2025 2026 2025 2025Revenue18.9 11.1 64.4 35.5 61.0Other operating income0.0 0.0 0.0 0.0 0.0Total operating income18.9 11.1 64.4 35.5 61.0Other external expenses-11.8 -13.2 -34.1 -38.7 -48.9 Personnel expenses-26.5 -13.6 -43.0 -63.3 -75.7 Depreciation and amortisation-0.8 -0.7 -2.3 -2.2 -2.9 Other operating expenses-0.1 -0.2 -0.3 -1.8 -2.1 Operating profit-20.3 -16.5 -15.3 -70.5 -68.6 Group contributions0.0 0.0 0.0 0.0 285.4Net financial items¹132.6 -7.5 370.2 -177.3 -212.4 Profit before tax112.2 -24.0 354.9 -247.9 4.5Income tax expense0.0 -16.1 0.0 -16.1 24.4Profit for the period112.2 -40.2 354.9 -264.0 28.9SEKm 30 Sep 2026 30 Sep 2025 31 Dec 2025 ASSETSNon current assetsOwn work capitalised 8.2 11.0 10.3Other intangible assets 0.8 - -Property, plant and equipment 0.1 0.2 0.2Shares in subsidiaries 6,604.7 6,242.1 6,254.3Receivables from group companies 7,574.2 7,175.4 6,840.1Deferred tax asset 40.6 - 40.6Other non current assets 16.7 - -Total non-current assets 14,245.3 13,428.7 13,145.5Current assetsReceivables from group companies 287.1 220.0 399.2Other receivables-0.00.22.5Prepaid expenses and accrued income 2.9 4.9 82.9Cash and cash equivalents - - -Total current assets290.0225.1484.6TOTAL ASSETS14,535.313,653.813,630.1EQUITY AND LIABILITIESEquityShare capital 0.9 0.9 0.9Development fund 8.3 13.1 10.3Fair value fund 16.7 - 2.5Share premium 8,420.5 8,387.9 8,381.1Retained earnings 2,135.9 2,064.4 2,084.2Profit for the period 354.9 -264.0 28.9Total equity 10,937.1 10,202.3 10,507.8Non-current liabilitiesBonds 1,699.7 1,607.0 1,607.0Liabilities to credit institutions 1,280.8 1,197.2 781.7Total non-current liabilities 2,980.4 2,804.2 2,388.7Current liabilitiesPayables to Group companies 596.7 594.3 680.7Trade payables3.42.26.7Other current liabilities 2.7 1.4 23.8Current income tax liabilities 0.8 0.4 0.4Accrued expenses and prepaid income 14.1 49.0 22.0Total current liabilities617.8647.3733.6TOTAL EQUITY AND LIABILITIES14,535.313,653.813,630.1
Page 20
Vimian Group Interim report January - September 2026 20 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1. Significant accounting policies The interim condensed consolidated financial statements comprise of the Swedish parent company Vimian Group AB (publ), with corporate identity number 559234-8923, and its subsidiaries. The Group’s primary operations are offering products and services in animal health for domestic pets and livestock around the world. The Group offers goods and services in medicine, diagnostics and medtech as well as services and advice for veterinary professionals. The Parent Company is a limited liability company with its registered office in Stockholm, Sweden. The address of the head office is Riddargatan 19, 114 57 Stockholm. The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and interpretations issued by the IFRS Interpretations Committee (IFRS IC) as adopted by the European Union (EU) and RFR1. The Group’s interim report is prepared in accordance with IAS 34 Interim financial reporting and applicable parts of the Swedish Annual Accounts Act (1995:1554). The interim report of the parent company is prepared in accordance with the Swedish Annual Accounts Act chapter 9, Interim financial reporting and Recommendation RFR 2 Accounting for Legal Entities. The Group and Parent Company have applied the same accounting principles, basis of calculation, and assumptions as those applied in the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2025. For a complete description of the Group’s and Parent Company’s applied accounting principles, see note 1 of the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2025. Disclosures according to IAS 34 are presented in the financial statements as well as corresponding notes on page 14-26, which are an integrated part of the interim condensed consolidated financial statements. All amounts are presented in millions of Euro (“MEUR”), unless otherwise indicated. Note 2. Key estimates and assumptions In preparing the interim financial statements, corporate management and the Board of Directors must make certain assessments and assumptions that impact the carrying amount of asset and liability items and revenue and expense items, as well as other information provided. The actual outcome may then differ from these assessments if other conditions arise. The key estimates and assumptions correspond to the ones described in the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2025. Significant estimates during the financial year 2026 concerns the value of the non-current receivable related to the US patent litigation. On 4 April 2023, Vimian’s subsidiary Veterinary Orthopedic Implants LLC (“VOI”) reached a settlement agreement with DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. resolving the patent dispute between the parties. Under the terms of the agreement, Vimian paid USD 70 million during the second quarter of 2023. In the indemnification dispute with the VOI sellers, VOI entered into settlement agreements with three of the four sellers in 2024. Each of the three sellers agreed to compensate Vimian for their entire pro rata shares of the USD 70 million settlement payment to DePuy Synthes. The total value of the three settlements amounts to approximately USD 32 million of which approximately USD 9 million has been contributed by means of dismissal of the contingent closing note from the acquisition of VOI. On 29 August 2025, the Superior Court of Delaware awarded Vimian USD 40.2 million in damages in the indemnification dispute with the largest seller of VOI. On 1 October 2025 the court confirmed the decision from 29 August. Together with the previously reached settlements with the other sellers, this means that Vimian is entitled to compensation exceeding the USD 70 million settlement paid by Vimian to DePuy Synthes. The largest seller appealed the court decision. The Supreme Court trial took place in Q2 in Dover, Delaware and rendered its opinion on 24 September 2026. The Supreme Court largely confirmed the win in the Superior Court. The Supreme Court decision cannot be appealed. During Q4 2025, the largest seller paid USD 31.9 million. The remaining debt from the largest seller amounts to USD 6.2 million. The payments received exceed the reported receivables on the seller by EUR 2.9 million. Vimian has not reported a provision for the on- going litigation and has also considered the remaining receivable on the seller as doubtful and therefore has not recorded any value in the financial statements. There are no changes in our assessment compared to year-end 2025.
Page 21
Vimian Group Interim report January - September 2026 21 Note 3. Operating segments 1 In MedTech, the majority of the acquisition related costs relate to the acquisitions of AllAccem and Dental Focus, closed in Q2-2025. ² Main items in other are severance pay to the former CEO. mEURJul-Sep 2026Revenue Revenue from external customers 50.3 43.2 7.4 19.3 120.3 - - 120.3Revenue from internal customers 0.0 0.0 0.0 0.1 0.2 - -0.2 -Total revenue 50.3 43.3 7.4 19.5 120.5 - -0.2 120.3 Adjusted EBITA 15.2 10.5 0.5 5.9 32.2 -3.0 -0.0 29.2Items affecting comparability -0.4 -1.2 -0.1 -0.4 -2.1 -0.0 - -2.1EBITA 14.8 9.4 0.4 5.5 30.1 -3.0 -0.0 27.1Amortisation of acquisition-related intangible assets -3.1 -2.3 -0.3 -0.9 -6.6 - - -6.6Net financial items -4.7 -6.8 -1.1 -3.0 -15.7 8.7 - -6.9Share of profit of an associate and joint venture - - -0.0 - -0.0 - - -0.0Profit before tax 7.0 0.3 -1.1 1.6 7.8 5.7 -0.0 13.6 Specification of items affecting comparability Acquisition-related costs 0.1 1.0 0.1 0.4 1.6 - - 1.6Systems update - - - - - - - -Restructuring costs 0.3 0.0 -0.0 -0.0 0.3 - - 0.3IPO and financing related costs - - - - - - - -Other -0.0 0.1 0.0 -0.0 0.2 0.0 - 0.2Total items affecting comparability 0.4 1.2 0.1 0.4 2.1 0.0 - 2.1 Other disclosures Investments 2.0 0.6 1.2 0.4 4.1 -0.0 - 4.1Total assets 539.0 470.5 85.0 195.8 1,290.4 775.7 -877.0 1,189.0Total liabilities 350.5 355.8 50.3 166.1 922.7 384.4 -877.0 430.1 Group total Eliminations Group functions Total segments Veterinary Services MedTech Specialty Pharma Diagnostics mEURJul-Sep 2025Revenue Revenue from external customers 46.2 37.1 5.2 15.8 104.3 - - 104.3Revenue from internal customers 0.0 0.0 - 0.0 0.1 - -0.1 -Total revenue 46.2 37.1 5.2 15.9 104.4 - -0.1 104.3 Adjusted EBITA 13.6 8.8 0.3 4.6 27.3 -1.8 0.0 25.5Items affecting comparability 0.0 -1.1 -0.1 0.0 -1.1 -0.5 - -1.7EBITA 13.6 7.8 0.2 4.6 26.2 -2.3 0.0 23.9Amortisation of acquisition-related intangible assets -3.0 -2.4 -0.2 -0.7 -6.3 - - -6.3Net financial items -2.1 -6.3 -0.2 0.2 -8.4 4.3 0.0 -4.1Share of profit of an associate and joint venture - - - - - - - -Profit before tax 8.5 -0.9 -0.3 4.1 11.4 2.0 0.0 13.4 Specification of items affecting comparability Acquisition-related costs¹ -0.0 0.6 0.1 -0.0 0.7 - - 0.7Systems update - 0.2 - -0.0 0.2 - - 0.2Restructuring costs -0.0 0.1 - - 0.1 - - 0.1IPO and financing related costs - - - - - -0.0 - -0.0Other² -0.0 0.1 0.0 - 0.1 0.5 - 0.6Total items affecting comparability -0.0 1.1 0.1 -0.0 1.1 0.5 - 1.7 Other disclosures Investments 1.9 0.7 0.3 0.5 3.3 - - 3.3Total assets 514.5 472.7 52.6 163.3 1,203.0 707.3 -787.8 1,122.5Total liabilities 343.6 359.0 34.3 131.0 867.9 346.7 -787.8 426.8 Specialty Pharma MedTech Diagnostics Total segments Group functions Eliminations Group total Veterinary Services
Page 22
Vimian Group Interim report January - September 2026 22 1 In Other the segments report paid compensation to the participants in the LTI 2022 programme. The cost is netted to the provision reported by Group functions in Q2-2025. 1 In MedTech the majority of the acquisition related costs relate to the acquisitions of iM3, AllAccem and Dental Focus. 2 Main items in other are legal fees related to the US indemnification dispute and provision for compensation to participants in the LTI 2022 programme. mEURJan-Sep 2026RevenueRevenue from external customers 149.0 130.4 22.2 56.2 357.9 - - 357.9Revenue from internal customers 0.0 0.0 0.0 0.2 0.3 - -0.3 -Total revenue 149.1 130.5 22.3 56.4 358.2 - -0.3 357.9 Adjusted EBITA 45.0 33.6 2.2 16.2 97.0 -8.9 0.0 88.1Items affecting comparability -0.7 -2.8 -0.5 -2.1 -6.1 1.3 - -4.8EBITA 44.3 30.9 1.7 14.1 91.0 -7.6 0.0 83.3Amortisation of acquisition-related intangible assets -9.3 -6.7 -0.9 -2.5 -19.3 - - -19.3Net financial items -12.9 -13.6 -1.2 -9.2 -36.9 18.7 - -18.2Share of profit of an associate and joint venture - - -2.5 - -2.5 - - -2.5Profit before tax 22.2 10.6 -3.0 2.5 32.2 11.1 -0.0 43.3 Specification of items affecting comparability Acquisition-related costs 0.1 1.5 0.4 1.2 3.2 - - 3.2Systems update - - - - - - - -Restructuring costs 0.3 0.0 0.0 0.1 0.4 - - 0.4IPO and financing related costs - - - - - - - -Other¹ 0.3 1.2 0.1 0.9 2.5 -1.3 - 1.2Total items affecting comparability 0.7 2.8 0.5 2.1 6.1 -1.3 - 4.8 Other disclosures Investments 8.3 3.3 2.6 1.3 15.5 0.1 - 15.6Total assets 539.0 470.5 85.0 195.8 1,290.4 775.7 -877.0 1,189.0Total liabilities 350.5 355.8 50.3 166.1 922.7 384.4 -877.0 430.1 Specialty Pharma MedTech Diagnostics Veterinary Services Total segments Group functions Eliminations Group total EURmJan-Sep 2025Revenue Revenue from external customers 136.4 115.4 16.8 47.5 316.1 - - 316.1Revenue from internal customers 0.0 0.0 - 0.2 0.2 - -0.2 -Total revenue 136.5 115.4 16.8 47.7 316.3 - -0.2 316.1 Adjusted EBITA 40.1 29.7 1.6 13.9 85.4 -6.2 - 79.2Items affecting comparability -0.5 -10.2 -0.2 -0.1 -11.1 -2.9 - -14.0EBITA 39.6 19.5 1.4 13.8 74.3 -9.1 - 65.2Amortisation of acquisition-related intangible assets -9.2 -5.6 -0.7 -2.1 -17.6 - - -17.6Net financial items -5.5 -15.3 -0.4 -0.5 -21.8 12.6 -4.0 -13.2Share of profit of an associate and joint venture - - - - - - - -Profit before tax 24.9 -1.4 0.3 11.2 35.0 3.4 -4.0 34.4 Specification of items affecting comparability Acquisition-related costs¹ 0.2 2.5 0.2 0.1 3.0 - - 3.0Systems update - 0.8 - 0.0 0.8 - - 0.8Restructuring costs 0.3 0.1 - - 0.4 - - 0.4IPO and financing related costs - - - - - 0.6 - 0.6Other² 0.0 6.8 0.0 - 6.9 2.3 - 9.2Total items affecting comparability 0.5 10.2 0.2 0.1 11.1 2.9 - 14.0 Other disclosures Investments 4.6 1.9 1.0 2.0 9.5 - - 9.5Total assets 514.5 472.7 52.6 163.3 1,203.0 707.3 -787.8 1,122.5Total liabilities 343.6 359.0 34.3 131.0 867.9 346.7 -787.8 426.8 Specialty Pharma MedTech Diagnostics Veterinary Services Total segments Group functions Eliminations Group total
Page 23
Vimian Group Interim report January - September 2026 23 Note 4. Revenue from contracts with customers The group has significant exposure to the US, 34 per cent (36) and the UK, 12 per cent (13) markets. All other markets individually represent less than 10 per cent of net revenue. Net revenue from external customers in Sweden amounted to EUR 3.9m (4.9) during the third quarter 2026. No individual customer accounts for more than 10 per cent of Group net revenue. EURmJul-Sep 2026Geographic regionEurope 28.4 14.5 5.1 14.5 62.4North America 18.1 22.1 1.0 3.9 45.2Rest of the World 3.8 6.7 1.3 0.9 12.7Revenue from contracts with customers 50.3 43.2 7.4 19.3 120.3Whereof from products 87%98%97%5%78%Whereof from services 13%2%3%95%22%Group total Veterinary Services Diagnostics MedTech Specialty Pharma EURmJul-Sep 2025Geographic regionEurope 24.7 10.7 3.3 12.5 51.1North America 18.0 19.8 0.9 2.6 41.4Rest of the World 3.56.61.00.711.8Revenue from contracts with customers 46.237.15.215.8104.3Whereof from products 84%99%98%4%78%Whereof from services 16% 1% 2% 96% 22%Specialty Pharma MedTech Diagnostics Veterinary Services Group total EURmJan-Sep 2026Geographic regionEurope 82.541.3 14.7 43.0 181.6North America 55.9 66.9 3.6 10.4 136.8Rest of the World 10.6 22.2 4.0 2.8 39.5Revenue from contracts with customers 149.0 130.4 22.2 56.2 357.9Whereof from products 87%98%97%5%79%Whereof from services 13%2%3%95%21%EURmJan-Sep 2025Geographic regionEurope 75.6 35.3 10.3 37.5 158.7North America 50.9 60.3 2.9 7.7 121.7Rest of the World 10.0 19.8 3.5 2.3 35.6Revenue from contracts with customers 136.4 115.3 16.8 47.5 316.0Whereof from products 84%99%97%5%79%Whereof from services 16%1%3%95%21% Specialty Pharma MedTech Diagnostics Veterinary Services Group total Group total Specialty Pharma MedTech Diagnostics Veterinary Services
Page 24
Vimian Group Interim report January - September 2026 24 Note 5. Financial instruments The carrying amount of the Group’s financial instruments measured at fair value regards contingent considerations (see below). The carrying amount of other financial assets and liabilities is deemed to be a good approximation of the fair value. Contingent consideration In some of the Group’s business combinations, part of the purchase price has been in the form of contingent consideration. The contingent considerations depend on the future earnings or sales of the acquired companies. The contingent considerations will be settled in cash. The contingent considerations are included in the following line items in the statement of financial position for 30 September 2026: other non-current liabilities EUR 24.4 million (28.8) and other current liabilities EUR 7.2 million (13.0). The contingent considerations are measured at fair value by discounting the expected cash flows by a risk adjusted discount rate. The contingent considerations are classified as level 3 in the fair value hierarchy. The contingent considerations consist of earn-out agreements in business combinations. The earn-out hurdles are typically linked to sales or EBITDA targets for periods ranging 1-5 years after the acquisition date. The earn-outs are discounted and revaluated on an ongoing basis, based on the current performance and forecasted figures for the acquired companies. There are currently 25 separate obligations, all with their own targets, capped at a maximum amount. The maximum amount payable if all acquisitions would reach their capped amounts is EUR 142.1 million. A 10 per cent increase in the underlying metric (sales or EBITDA) for all acquisitions compared to the current assumptions would lead to an increase of the contingent consideration of EUR 10.4 million. Note 6. Business combinations The following acquisitions have been completed during the period January – September 2026: I-Vet s.r.l. On 2 March 2026, the Group acquired 100% of the shares in I-Vet. I-Vet is one of the leading providers of companion animal diagnostics in Italy with annual revenues of around EUR 5.6 million. Favna ApS On 5 March 2026, the Group acquired 70% of the shares in Favna, that operates veterinary clinics in Denmark, with annual revenues of around EUR 4.3 million. VetSave Ltd On 1 May 2026, the Group acquired 100% of the shares in VetSave. VetSave, with annual revenues of around EUR 1.7 million, provides veterinary practices with buying group services and offers a fully transparent solution to the true cost of veterinary medicines, with all rebates and discounts on the day of purchase. Verona Pet On 13 July 2026, the Group acquired the assets of the Verona Pet cremation services in Italy. The business has annual revenues of EUR 0.4 million. Contingent consideration, EURmJan-Sep 2026 Jan-Sep 2025 Jan-Dec 2025Opening balance 46.4 63.7 63.7Business combinations 8.5 7.9 8.3Paid out -29.4 -33.4 -33.6Change in fair value recognised in P&L 2.9 3.6 5.5Probability adjustments recognised in the P&L 2.4 1.5 4.1Exchange differences on translation of foreign operations 0.7 -1.5 -1.5Closing balance 31.6 41.8 46.4EURmDeal type Acquired % Based Segment Consolidation month Annual sales I-Vet s.r.l. Share 100% Italy Diagnostics Mar 5.6Favna ApS Share 70% DenmarkVeterinary services Mar 4.3VetSave Ltd Share 100% IrelandVeterinary services May 1.7Verona Pet Assets Italy Diagnostics Jul 0.4
Page 25
Vimian Group Interim report January - September 2026 25 Preliminary purchase price allocations per operating segment during the period January – September 2026 The purchase price allocations of I-Vet, Favna, VetSave and Verona Pet are deemed preliminary. The group does not expect any material deviations from the current numbers. Acquired net assets on acquisition date based on preliminary PPA, EURmSpecialty Pharma MedTech Diagnostics Veterinary Services Group total Intangible assets 5.0 6.7 11.7Property, plant and equipment 2.6 0.4 2.9Right-of-use assets - - -Non-current financial assets 0.5 0.1 0.6Deferred tax assets - - -Inventories 1.2 0.2 1.4Trade receivable and other receivables 1.8 6.9 8.7Cash and cash equivalents 0.1 0.4 0.5Interest-bearing liabilities -4.1 - -4.1Lease liabilities - - -Deferred tax liabilities -1.6 -0.9 -2.4Trade payables and other operating liabilities -2.2 -8.2 -10.3Identified net assets 3.3 5.5 8.8 Non-controlling interest measured at fair value - - -Goodwill 16.9 10.3 27.2Total purchase consideration 20.2 15.8 36.0 Purchase consideration comprises: Cash 14.8 11.6 26.4Equity instruments - - -Contingent consideration and deferred payments 5.3 4.2 9.5Total purchase consideration 20.2 15.8 36.0Impact of acquisition on Group’s cash flow, EURmSpecialty Pharma MedTech Diagnostics Veterinary Services Group total Cash portion of purchase consideration 14.8 11.6 26.4Acquired cash -0.1 -0.4 -0.5Total 14.7 11.2 25.9Acquisition-related costs 0.7 0.6 1.2Net cash outflow 15.3 11.8 27.2
Page 26
Vimian Group Interim report January - September 2026 26 Note 7. Related-party transactions There have been no significant changes in the relationships with related parties for the Group or the Parent Company compared to the information provided in the Annual Financial statements for 2025. All related party transactions are at arm’s length. Year to date an amount of EUR 7.7m in licensing income was invoiced to an entity owned by Nick Bova, manager within the Specialty Pharma segment, that owns Pharmacy licenses as part of regulatory restrictions. Other related party transactions include rent and fee payments to former owners of acquired businesses. The amounts paid in these transactions are insignificant both individually and as a whole. Note 8. Events after the balance-sheet date No significant events occurred after the end of the third quarter. Note 9. Seasonal effects and risks Seasonal effects Vimian assesses that its revenues and EBITA to a limited degree are affected by seasonality. The four segments have varying, but limited, seasonality patterns. The strongest seasonality effect can be seen in MedTech, where the first quarter is typically the strongest quarter due to the AOP programme. During 2024 and 2025, Vimian has reduced the AOP to better align shipments with customer demand for the MedTech segment. As a consequence, the revenue will be more evenly spread throughout the year with limited seasonality for MedTech. For all segments, trading volumes are slightly negatively affected by holiday periods. Risks and uncertainties Vimian Group’s and the parent company’s business risks and risk management, as well as the management of financial risks, are described on pages 64-69 in the 2025 Annual Report published at www.vimian.com. The group has limited exposure to the current geopolitical environment, mainly being the international supply chain for both finished products and raw materials. In case of tariffs or conflicts this could hurt the groups competitive advantage in certain businesses. To mitigate these risks the group is diversifying its supply chains and implementing contingency plans.
Page 27
Vimian Group Interim report January - September 2026 27 Note 10. Restatement of Statement of profit and loss As from the fourth quarter 2025, Vimian has changed the accounting of elimination of internal management fees. The elimination was previously netting Other operating income and Other external expenses. The change has no other effect on the financial statements. Comparative periods have been restated accordingly. Note 11. IFRS 18 implementation IFRS 18 becomes effective for financial years beginning on or after 1 January 2027 and will be applied by Vimian from that date. The standard is to be applied retrospectively to all comparative periods. As IFRS 18 affects only presentation and disclosures and not the measurement of items in the financial statements, the transition is not expected to impact retained earnings. The primary effects relate to the structure of the income statement, where certain items will be reclassified and new subtotals, such as operating profit, will be introduced. Comparative figures will be restated, and a reconciliation between the previous presentation under IAS 1 and the new presentation under IFRS 18 will be provided. The final analysis of the transition effects and disclosures, as well as the assessment of Management Performance Measures (MPM), is still ongoing. EURm Reported Restated Reported RestatedJan-mar 2025 -0.1 0.7 -23.1 -23.9Apr-jun 2025 -0.1 1.0 -20.6 -21.7Jan-jun 2025 -0.2 1.7 -43.8 -45.7Jul-sep 2025 -0.1 0.6 -18.0 -18.7Jan-sep 2025 -0.3 2.3 -61.8 -64.4 Other external expensesOther operating income
Page 28
Vimian Group Interim report January - September 2026 28 ALTERNATIVE PERFORMANCE MEASURES Alternative Performance Measures (APMs) are financial measures of historical or future financial performance, financial position or cash flows that are not defined in applicable accounting regulations (IFRS). APMs are used by Vimian when it is relevant to monitor and describe Vimian’s financial situation and to provide additional useful information to users of financial statements. These measures are not directly comparable to similar key ratios presented by other companies. Key Ratios Definition Reason for usage Organic Revenue Growth Change in Revenue in relation to the comparative period adjusted for acquisition and divestment effects and any currency impacts. Acquired businesses are included in Organic growth when they have been part of the Group for 12 months and divested businesses are excluded from Organic growth from the date of divestment in the current and comparative period. The Currency impact is calculated by translating the accounts for year N-1 of subsidiaries having a functional currency different than the currency of the issuer with N exchange rate. Organic growth is used by investors, analysts and the company’s management to monitor the underlying development of revenue between different periods at constant currency and excluding the impact of any acquisitions and/or divestments. EBIT Operating profit as reported in the Income statement, i.e. profit for the period excluding finance income, finance costs, share of profit of an associate and income tax expense. The measure shows the profitability from the operations of the parent company and its subsidiaries. EBITA Operating profit excluding amortisation of intangible assets that were originally recognised in connection with business combinations. The measure reflects the business’s operating profitability and enables comparison of profitability over time, regardless of amortisation of intangible assets as well as independent of taxes and the Company’s financing structure. EBITDA Operating profit excluding amortisation, depreciation and impairment of intangible and tangible assets. The measure reflects the business’s operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company’s financing structure. Adjusted EBITA EBITA adjusted for items affecting comparability. The measure reflects the business’s operating profitability and enables comparison of profitability over time, regardless of amortisation of intangible assets as well as independent of taxes and the Company’s financing structure. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time. Adjusted EBITA margin Adjusted EBITA in relation to Revenue. The measure reflects the business’s operating profitability before amortisation of intangible assets. The measure is an important component, together with revenue growth, to follow the Company’s value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time. Adjusted EBITDA EBITDA adjusted for items affecting comparability. The measure reflects the business’s operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company’s financing structure. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time. Adjusted EBITDA margin Adjusted EBITDA in relation to Revenue. The measure reflects the business’s operating profitability before amortisation and depreciation of intangible and tangible fixed assets. The measure is an important component, together with revenue growth, to follow the Company’s value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time. Items affecting comparability Income and expense items that are considered to be important to specify to users of the financial information since they affect comparability. A separate disclosure of items affecting comparability is relevant to provide to users of the financial information to give further understanding of the financial performance when comparing of financial performance between periods. Generally accepted NRI’s include acquisition and integration related costs, litigation related costs if material, significant restructuring costs (e.g., the consolidation of production footprint in Diagnostics going from four to two production sites), costs related to projects such as the initial public offering.
Page 29
Vimian Group Interim report January - September 2026 29 Key Ratios Definition Reason for usage Amortisation PPA related Amortisation of intangible assets that were originally recognised in connection with business combinations. Specification of amortisation in different categories since management differentiates amortisation when calculating EBITA. Net debt Cash and cash equivalents less liabilities to credit institutions, lease liabilities, other non-current liabilities and specific items included in other current liabilities (contingent considerations, deferred payments, vendor notes and shareholder loans related to business combinations). Net debt is a measure used to follow the development of debt and the size of the refinancing need. Since cash and cash equivalents can be used to pay off debt at short notice, net debt is used instead of gross debt as a measure of the total loan financing. Net debt / Adjusted EBITDA (pro-forma) Net debt in relation to a 12-month period of Adjusted EBITDA (pro-forma). The measure is a debt ratio that shows how many years it would take to pay off the Company’s debt, provided that its net debt and Adjusted EBITDA are constant and without taking into account the cash flows regarding interest, taxes and investments. Net Debt / Adjusted EBITDA is referred to in the report as leverage. Net Working Capital Inventory, Trade receivables, Current tax receivables, Other current receivables, Prepaid expenses and Accrued income, less Trade payables, Current tax liabilities, Accrued expenses and deferred income, Provisions and Other current liabilities (excluding contingent considerations, deferred payments, vendor notes and shareholder loans related to business combinations) Working capital is a measure of the company’s short-term financial status Capex Total cash flow from investments in tangible and intangible assets during the period. This includes costs for internally developed assets. Capex is a measure of the company’s historical investments and is used as input in calculating Free cash flow and Cash conversion. Proforma revenue Reported revenue for the last twelve months plus revenue for all acquisitions closed during the last twelve months, as if they had been consolidated the full period. The measure reflects a fair view of the business’s revenue for a full year period. Adjusted EBITA, Proforma Reported adjusted EBITA for the last twelve months adding the adjusted EBITA for all acquisitions closed during the last twelve months, as if they had been consolidated the full period. The measure reflects the business’s operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company’s financing structure. The measure is adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period. Adjusted EBITDA, Proforma Reported adjusted EBITDA for the last twelve months adding the adjusted EBITDA for all acquisitions closed during the last twelve months, as if they had been consolidated the full period. The measure reflects the business’s operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company’s financing structure. The measure is adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period. Adjusted EBITA and EBITDA margin, Proforma Adjusted proforma EBITA and EBITDA in relation to proforma revenue. The measure reflects the business’s operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company’s financing structure. The measure is an important component, together with revenue growth, to follow the Company’s value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period. Acquisition related expenses Expenses related to legal and financial due diligence as well as in some cases stay on bonuses to key personnel. If specific initial integration costs are required, and agreed upon during the acquisition process, this can be considered as acquisition related expenses. Restructuring costs Costs relating to significant change of business model or operational structure. Possibly linked to integration between legacy and acquired businesses. The most significant restructuring project to date is the consolidation of production footprint in Diagnostics going from four to two production sites.
Page 30
Vimian Group Interim report January - September 2026 30 Alternative performance measures not defined in accordance with IFRS for the group - Based on proforma figures 1 Jan-31 DecEURm (unless otherwise stated)2026 2025 2026 2025 2025Revenue growth (%)15% 19% 13% 17% 13%Organic revenue growth (%)11% 9% 10% 6% 6%Revenue120.3 104.3 357.9 316.1 425.0EBITDA31.8 27.4 96.0 75.4 104.8EBITDA margin (%)26.5% 26.3% 26.8% 23.9% 24.7%Items affecting comparability-2.1 -1.7 -4.8 -14.0 -14.7Adjusted EBITDA33.9 29.1 100.8 89.4 119.5Adjusted EBITDA margin (%)28.2% 27.9% 28.2% 28.3% 28.1%EBITA27.1 23.9 83.3 65.2 90.7EBITA margin (%)22.5% 22.9% 23.3% 20.6% 21.3%Adjusted EBITA29.2 25.5 88.1 79.2 105.3Adjusted EBITA margin (%)24.3% 24.5% 24.6% 25.1% 24.8%Operating profit20.5 17.5 64.0 47.6 66.8Operating margin (%)17.0% 16.8% 17.9% 15.1% 15.7%Capital expenditure-4.1 -3.1 -15.6 -9.3 -15.1Cash flow from operating activities22.6 10.8 49.4 50.1 105.7 1 Jul-30 Sep1 Jan-30 Sep 1 Oct - 30 SepEURm (unless otherwise stated)LTM (2025/2026)Proforma revenue472.5Adjusted EBITDA, Proforma132.3Adjusted EBITDA margin, Proforma28.0%Net debt262.4Net debt / Adjusted EBITDA, Proforma (x)2.0x
Page 31
Vimian Group Interim report January - September 2026 31 Reconciliation of alternative performance measures not defined in accordance with IFRS for the group Certain statements and analyses presented include alternative performance measures (APMs) that are not defined by IFRS. The Company believes that this information, together with comparable defined IFRS metrics, are useful to investors as they provide a basis for measuring operating profit and ability to repay debt and invest in operations. Corporate management uses these financial measurements, along with the most directly comparable financial metrics under IFRS, to evaluate operational results and value added. The APMs should not be assessed in isolation from, or as a substitute for, financial information presented in the financial statements in accordance with IFRS. The APMs reported are not necessarily comparable to similar metrics presented by other companies. The reconciliations are presented in the tables below: 1 Shareholder loans, deferred payments, vendor notes and contingent considerations included in other current liabilities 2 Other current liabilities as reported in the statement of financial position less shareholder loans, deferred payments, vendor notes and contingent considerations related to business combinations 1 Jan-31 DecEURm (unless otherwise stated)2026 2025 2026 2025 2025EBITA/EBITDA and Adjusted EBITA/EBITDARevenue120.3 104.3 357.9 316.1 425.0EBIT20.5 17.5 64.0 47.6 66.8Amortisation of acquisition related intangibles6.6 6.3 19.3 17.6 23.8EBITA27.1 23.9 83.3 65.2 90.7Other depreciation4.7 3.5 12.7 10.2 14.1EBITDA31.8 27.4 96.0 75.4 104.8Items affecting comparability2.1 1.7 4.8 14.0 14.7Adjusted EBITA29.2 25.5 88.1 79.2 105.3Adjusted EBITDA33.9 29.1 100.8 89.4 119.5EBITA margin (%)22.5% 22.9% 23.3% 20.6% 21.3%EBITDA margin (%)26.5% 26.3% 26.8% 23.9% 24.7%Adjusted EBITA margin (%)24.3% 24.5% 24.6% 25.1% 24.8%Adjusted EBITDA margin (%)28.2% 27.9% 28.2% 28.3% 28.1% 1 Jul-30 Sep1 Jan-30 Sep 31 DecEURm (unless otherwise stated)2026 2025 2025Net debtLiabilities to credit institutions (long term)263.1 254.0 223.3Lease liabilities (long term)12.1 11.0 10.3Other non-current liabilities28.2 28.8 20.9Liabilities to credit institutions (short term)0.0 -0.2 0.0Lease liabilities (short term)5.0 5.0 5.1Other items¹10.1 30.7 42.3Cash & Cash Equivalents-55.6 -51.3 -55.0Other receivables-0.6 -24.6 -1.5Net debt262.4 253.5 245.430 Sep 31 DecEURm (unless otherwise stated)2026 2025 2025Net working capitalInventory98.3 80.9 80.1Trade receivables67.5 57.6 57.3Current tax receivables4.5 2.2 1.2Other current receivables6.9 8.5 6.7Prepaid expenses and accrued income14.6 12.2 13.2Trade payables-28.1 -18.5 -20.1Current tax liabilities-10.3 -10.6 -10.3Other current liabilities²-11.3 -8.3 -11.5Provisions-1.6 -0.3 -0.8Accrued expenses and deferred income-24.1 -21.4 -19.2Net working capital116.4 102.2 96.6 30 Sep
Page 32
Vimian Group Interim report January - September 2026 32 1 Oct - 30 Sep1 Jan-31 DecEURm (unless otherwise stated)LTM (2025/2026) 2025Proforma revenueReported revenue466.9 425.0Proforma period, revenue5.6 5.3Proforma revenue472.5 430.4Adjusted EBITA, ProformaReported Adjusted EBITA (12 months)114.3 105.3Proforma period Adjusted EBITA1.3 3.6Adjusted EBITA, Proforma115.6 108.9Adjusted EBITA margin, ProformaProforma Revenue472.5 430.4Adjusted EBITA, Proforma115.6 108.9Adjusted EBITA margin, Proforma24.5% 25.3%Adjusted EBITDA, ProformaReported Adjusted EBITDA (12 months)130.9 119.5Proforma period Adjusted EBITDA1.5 3.7Adjusted EBITDA, Proforma132.3 123.1Adjusted EBITDA margin, ProformaProforma Revenue472.5 430.4Adjusted EBITDA, Proforma132.3 123.1Adjusted EBITDA margin, Proforma28.0% 28.6%Net debt/Adjusted EBITDA, ProformaNet debt262.4 245.4Adjusted EBITDA, Proforma132.3 123.1Net debt/Adjusted EBITDA, Proforma (x)2.0x 2.0x
Page 33
Financial calendar 24 November 2026 Capital Markets Day 11 February 2027 Year-end report 2026 28 April 2027 Interim Report Q1 2027 Annual General Meeting 16 July 2027 Interim Report Q2 2027 21 October 2027 Interim Report Q3 2027 For further information, please contact Carl-Johan Zetterberg Boudrie CFO carl-johan.zetterberg@vimian.com +46 703 35 84 49 Maria Dahllöf Tullberg Head of IR, Communications & ESG maria.tullberg@vimian.com +46 736 26 88 86 Vimian Group AB (publ) Reg. no. 559234-8923 Riddargatan 19 114 57 Stockholm Sweden www.vimian.com